Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 315 followers
Latest posts
Last updated 2 minutes ago
GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots
44 minutes ago
GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time...
Medtronic backs push to activate heart valve disease patients as TAVR marketing heats up
about 6 hours ago
Medtronic backs push to activate heart valve disease patients as TAVR marketing...
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB
about 12 hours ago
Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer...
Fierce Pharma Asia—Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout
about 14 hours ago
Fierce Pharma Asia—Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu...
Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy
about 20 hours ago
Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs...
Bristol Myers Squibb leans on long-term growth drivers, strategy overhaul to dodge IRA impacts
about 22 hours ago
Bristol Myers Squibb leans on long-term growth drivers, strategy overhaul to dodge...
'The Top Line': A look at pharma revenue rankings
about 23 hours ago
'The Top Line': A look at pharma revenue rankings aellison Thu, 04/25/2024...
Sanofi leans on COPD as 'next major growth pillar' for its immunology star Dupixent: CEO
about 23 hours ago
Sanofi leans on COPD as 'next major growth pillar' for its immunology...
Merck CEO Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff'
about 24 hours ago
Merck CEO Davis dubs Keytruda market exclusivity loss as 'more of a...
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy
about 24 hours ago
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand...
Neurocrine spotlights challenges of congenital adrenal hyperplasia patients with ‘What the C@H?!’ campaign
about 24 hours ago
Neurocrine spotlights challenges of congenital adrenal hyperplasia patients with ‘What the C@H?!’...
Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters new phase
1 day ago
Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters...